After 43+ years working for one investment research company or another, I finally retired. So now, I’m completely independent. And for the first time on Seeking Alpha, I won’t be working based on anybody else’s product agenda. I have only one goal now… to give you the best actionable investment insights I can.I have long specialized in rules/factor-based equity investing strategies. But I’m different from others who share such backgrounds. I don’t serve the numbers. Instead, the numbers serve me… to inspire ...

Core Insights - The article discusses the author's transition to independent investment research after over 43 years in the industry, emphasizing a focus on actionable investment insights rather than adhering to external agendas [1] Group 1: Investment Philosophy - The company specializes in rules and factor-based equity investing strategies, prioritizing human intelligence over purely quantitative methods [1] - The approach combines factor analysis with classic fundamental analysis to uncover the true story of a company and its stock, aiming to predict future performance rather than relying solely on historical data [1] Group 2: Professional Background - The author has extensive experience covering a wide range of stocks, including large cap, small cap, micro cap, value, growth, and income [1] - Previous roles include managing a high-yield fixed-income fund and conducting research on quantitative asset allocation strategies, contributing to the development of Robo Advising [1] - The author has also edited and written stock newsletters, notably the Forbes Low Priced Stock Report, and served as an assistant research director at Value Line [1] Group 3: Educational Contributions - A strong passion for investor education is highlighted, with numerous seminars conducted on stock selection and analysis, along with the authorship of two books: "Screening The Market" and "The Value Connection" [1]

April 22, 2025 09:00 PM GMT China Healthcare | Asia Pacific SMID-Cap CRO/CDMOs: Impacts from Potential Tariffs and FDA Animal Testing Rules Direct CMO tariff exposure of major China CRO/CDMO names is no more than 10%, while increasing macro uncertainties beyond tariffs could dampen funding beta. FDA proposal to phase out animal testing has limited impact on our covered pre-clinical CROs in 2025. Key Takeaways Higher tariffs + Increasing uncertainty = Softer funding beta + more cautious R&D budget: The direc ...

Expeditors International of Washington (EXPD) Update / Briefing January 28, 2025 11:00 AM ET Company Participants Sarah Maas - Regional Sales OperationsJamie Childress - Regional Risk & Insurance Manager Sarah Maas Alright. So it is 10 o'clock. So we'll get started. So for those of you who have just joined, thank you for joining us today for our IngoTerms Basics webinar. As you can see, we have a poll for you to answer. And my name is Sarah Mas, and I am the regional sales operations and marketing lead for ...